The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer.

The almost insignificant loss of cell viability induced by trastuzumab in both parental and negative control shRNA-transduced cells ( i.e. , 1% reduction at 1 μg/mL trastuzumab and 8% reduction at 100 μg/mL trastuzumab) were significantly augmented in ATG8/LC3 shRNA/JIMT1 cells ( i.e. , from 19% reduction at 1 μg/mL trastuzumab to 30% reduction at 100 μg/mL trastuzumab).

also in 529 other papers